At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 660 enrolled
Drug / intervention
Biological: mRNA-1273 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older
In Brief
A Phase 2 clinical trial evaluating Biological: mRNA-1273, Placebo, and 1 other intervention for SARS-CoV-2. Completed, enrolled 660 participants across 8 sites.
Detailed Summary
This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesUnited States
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartMay 2020
Primary CompletionOct 2021
TodayJul 2026
First PostedMay 28, 2020
Enrollment StartMay 29, 2020
Primary CompletionOct 28, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.1 years ago
Interventions
Biological: mRNA-1273biological
Sterile liquid for injection
Placebobiological
0.9% sodium chloride (normal saline) injection
mRNA-1273.351biological
Sterile liquid for injection